Viatris Inc. (VTRS)
NASDAQ: VTRSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
VTRS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $20.09B
- Forward P/E
- 6.54
- EPS (TTM)
- -$0.36
- Dividend yield
- 2.74% ($0.48)
- Ex-dividend date
- Aug 21, 2026
- 52-week range
- 9.69 – 18.43
- Day range
- 17.41 – 17.82
- Volume / Avg
- 7.54M / 9.20M
- Beta
- —
- Shares outstanding
- 1.15B
- Next earnings
- Nov 5, 2026
52-week range
VTRS stock today
Shares of Viatris (VTRS) finished lower on Oct 7 at $17.49, a drop of 0.29% or $0.05 per share, versus the S&P 500's 0.22% decline. Shares are 5.1% below their 52-week high of $18.43, set on Sep 29, 2026 and 80.5% above the 52-week low of $9.69, near the top of the past year's range. VTRS is up 40.5% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 72.5%.
Viatris has posted a net loss over the last twelve months (EPS of -$0.36), so its P/E ratio is not meaningful. Viatris's next earnings report is expected on Nov 5, 2026. Viatris pays an annual dividend of $0.48 per share, a 2.74% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Viatris
Company profileViatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Scott Andrew Smith Ph.D.
- Headquarters
- Canonsburg, PA
- Employees
- 30,000
- Website
- viatris.com
Financial highlights
Full financialsIn fiscal 2025, Viatris generated $14.30 billion in revenue, down 3.0% from fiscal 2024, its first annual decline since 2024. Viatris reported a net loss of $3.51 billion, compared with a loss of $634.2 million a year earlier. Gross margin was 35.1% (down from 38.2%) and operating margin -18.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $14.30B | $14.74B | $15.43B | $16.26B | $17.89B |
| Growth | -2.98% | -4.46% | -5.14% | -9.08% | +49.73% |
| Net income | $-3.51B | $-634.20M | $54.70M | $2.08B | $-1.27B |
| EPS (diluted) | $-3.00 | $-0.53 | $0.05 | $1.71 | $-1.05 |
Analyst forecast
ForecastConsensus (12 analysts)
buy
Avg. price target
$19.70+12.64%
- Strong buy 1
- Buy 6
- Hold 4
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $0.65
- Last reported (Q2 2026)
- Aug 6, 2026
- EPS actual vs est.
- $-0.10 vs —
Dividends
Dividend history- Annual dividend
- $0.48
- Dividend yield
- 2.74%
- Last payment
- $0.12
- Ex-dividend date
- Aug 21, 2026
VTRS news
All VTRS newsViatris peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| INSMInsmed Incorporated | 101.74 | -3.32% | $22.22B | vs VTRS |
| GMABGenmab A/S ADS | 36.65 | -3.04% | $22.54B | vs VTRS |
| UTHRUnited Therapeutics Corporation | 545.00 | +0.62% | $23.38B | vs VTRS |
| ROIVRoivant Sciences Ltd. | 34.75 | -2.20% | $25.10B | vs VTRS |
| ASNDAscendis Pharma A/S | 228.41 | +1.04% | $15.03B | vs VTRS |
| JAZZJazz Pharmaceuticals plc | 231.19 | -0.09% | $15.01B | vs VTRS |
| SMMTSummit Therapeutics Inc. | 17.95 | +3.70% | $14.32B | vs VTRS |
| BBIOBridgeBio Pharma Inc. | 66.50 | -0.69% | $13.00B | vs VTRS |
Indexes, lists and sector
Index membership
Appears in lists
Viatris stock FAQ
What is Viatris's stock price today?
VTRS last traded at $17.49 as of Oct 7, 4:00 PM EDT, down 0.29% on the day. Prices are delayed at least 15 minutes.
Does Viatris pay a dividend?
Yes. Viatris pays $0.48 per share annually, a 2.74% yield. The most recent dividend of $0.12 had an ex-dividend date of Aug 21, 2026.
When is Viatris's next earnings date?
Viatris is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $0.65.
Is Viatris in the S&P 500?
Yes. Viatris (VTRS) is a constituent of the S&P 500 index.
Who is Viatris's CEO?
Mr. Scott Andrew Smith Ph.D. is the chief executive officer of Viatris Inc., which has about 30,000 employees.
Has VTRS ever split its stock?
Yes. The most recent VTRS stock split was a 3-for-2 split on Oct 9, 2003, one of 4 splits on record.
What is the VTRS 52-week high?
The 52-week high for VTRS is $18.43 and the 52-week low is $9.69. The stock is currently 5.1% below its high.